These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

415 related articles for article (PubMed ID: 33503955)

  • 1. A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin.
    Fan D; Yang H; Mao W; Rask PJ; Pang L; Xu C; Vankayalapat H; Ahmed AA; Bast RC; Lu Z
    Cancers (Basel); 2021 Jan; 13(3):. PubMed ID: 33503955
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel.
    Zhou J; Alfraidi A; Zhang S; Santiago-O'Farrill JM; Yerramreddy Reddy VK; Alsaadi A; Ahmed AA; Yang H; Liu J; Mao W; Wang Y; Takemori H; Vankayalapati H; Lu Z; Bast RC
    Clin Cancer Res; 2017 Apr; 23(8):1945-1954. PubMed ID: 27678456
    [No Abstract]   [Full Text] [Related]  

  • 3. The Small-Molecule Inhibitor MRIA9 Reveals Novel Insights into the Cell Cycle Roles of SIK2 in Ovarian Cancer Cells.
    Raab M; Rak M; Tesch R; Gasimli K; Becker S; Knapp S; Strebhardt K; Sanhaji M
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
    Ahmed AA; Lu Z; Jennings NB; Etemadmoghadam D; Capalbo L; Jacamo RO; Barbosa-Morais N; Le XF; ; Vivas-Mejia P; Lopez-Berestein G; Grandjean G; Bartholomeusz G; Liao W; Andreeff M; Bowtell D; Glover DM; Sood AK; Bast RC
    Cancer Cell; 2010 Aug; 18(2):109-21. PubMed ID: 20708153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Salt-inducible kinase 2 regulates mitotic progression and transcription in prostate cancer.
    Bon H; Wadhwa K; Schreiner A; Osborne M; Carroll T; Ramos-Montoya A; Ross-Adams H; Visser M; Hoffmann R; Ahmed AA; Neal DE; Mills IG
    Mol Cancer Res; 2015 Apr; 13(4):620-635. PubMed ID: 25548099
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The insulin-like growth factor-I receptor kinase inhibitor, NVP-ADW742, sensitizes small cell lung cancer cell lines to the effects of chemotherapy.
    Warshamana-Greene GS; Litz J; Buchdunger E; García-Echeverría C; Hofmann F; Krystal GW
    Clin Cancer Res; 2005 Feb; 11(4):1563-71. PubMed ID: 15746061
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of miR-203 sensitizes paclitaxel (Taxol)-resistant colorectal cancer cells through targeting the salt-inducible kinase 2 (SIK2).
    Liu Y; Gao S; Chen X; Liu M; Mao C; Fang X
    Tumour Biol; 2016 Sep; 37(9):12231-12239. PubMed ID: 27236538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of phosphatidylinositol 3-kinase sensitizes ovarian cancer cells to carboplatin and allows adjunct chemotherapy treatment.
    Westfall SD; Skinner MK
    Mol Cancer Ther; 2005 Nov; 4(11):1764-71. PubMed ID: 16275998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SIK2 promotes reprogramming of glucose metabolism through PI3K/AKT/HIF-1α pathway and Drp1-mediated mitochondrial fission in ovarian cancer.
    Gao T; Zhang X; Zhao J; Zhou F; Wang Y; Zhao Z; Xing J; Chen B; Li J; Liu S
    Cancer Lett; 2020 Jan; 469():89-101. PubMed ID: 31639424
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of a novel histone deacetylase inhibitor panobinostat (LBH589) on the growth of ovarian cancer.
    Garrett LA; Growdon WB; Rueda BR; Foster R
    J Ovarian Res; 2016 Sep; 9(1):58. PubMed ID: 27633667
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.
    Helland Ø; Popa M; Bischof K; Gjertsen BT; McCormack E; Bjørge L
    PLoS One; 2016; 11(6):e0158208. PubMed ID: 27352023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salt-Inducible Kinase 2-Triggered Release of Its Inhibitor from Hydrogel to Suppress Ovarian Cancer Metastasis.
    Hua Y; Yin H; Liu X; Xie J; Zhan W; Liang G; Shen Y
    Adv Sci (Weinh); 2022 Aug; 9(22):e2202260. PubMed ID: 35618488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long non-coding RNA UCA1 promotes the progression of paclitaxel resistance in ovarian cancer by regulating the miR-654-5p/SIK2 axis.
    Li ZY; Wang XL; Dang Y; Zhu XZ; Zhang YH; Cai BX; Zheng L
    Eur Rev Med Pharmacol Sci; 2020 Jan; 24(2):591-603. PubMed ID: 32016960
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK.
    Shi X; Yu X; Wang J; Bian S; Li Q; Fu F; Zou X; Zhang L; Bast RC; Lu Z; Guo L; Chen Y; Zhou J
    Mol Oncol; 2022 Jul; 16(13):2558-2574. PubMed ID: 35278271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Alteration of survivin gene expression in ovarian cancer cell line CAOV3 after chemotherapy in vitro].
    Zhang SL; Jiang T; Lin B; Zhao CQ; Meng LR
    Zhonghua Fu Chan Ke Za Zhi; 2004 Jul; 39(7):482-5. PubMed ID: 15347474
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Effects of hyperthermia combined platinum-based drugs on ovarian cancer cell lines SKOV3].
    Xie D; Yin RT; Li KM; Xiao P; Tong LX
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2014 Jul; 45(4):606-11. PubMed ID: 25286685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Selective SIK2 Inhibitor ARN-3236 Produces Strong Antidepressant-Like Efficacy in Mice via the Hippocampal CRTC1-CREB-BDNF Pathway.
    Liu Y; Tang W; Ji C; Gu J; Chen Y; Huang J; Zhao X; Sun Y; Wang C; Guan W; Liu J; Jiang B
    Front Pharmacol; 2020; 11():624429. PubMed ID: 33519490
    [TBL] [Abstract][Full Text] [Related]  

  • 19. S100A10 silencing suppresses proliferation, migration and invasion of ovarian cancer cells and enhances sensitivity to carboplatin.
    Wang L; Yan W; Li X; Liu Z; Tian T; Chen T; Zou L; Cui Z
    J Ovarian Res; 2019 Nov; 12(1):113. PubMed ID: 31739800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotensin Receptor 1 Antagonist SR48692 Improves Response to Carboplatin by Enhancing Apoptosis and Inhibiting Drug Efflux in Ovarian Cancer.
    Liu J; Agopiantz M; Poupon J; Wu Z; Just PA; Borghese B; Ségal-Bendirdjian E; Gauchotte G; Gompel A; Forgez P
    Clin Cancer Res; 2017 Nov; 23(21):6516-6528. PubMed ID: 28790113
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.